Trial Profile
A Phase I Single-Dose Open-Label Two-Way Fixed-Sequence Study Evaluating The Effect Of Rolapitant On The Radiolabeled NK-1 ligand Tracer [11C]-GR205171 In The Brains Of Healthy Volunteers Using PET Imaging: PET Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2017
Price :
$35
*
At a glance
- Drugs Rolapitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors TESARO
- 10 Feb 2017 New trial record
- 31 Jan 2017 Results published in the Clinical Pharmacology and Therapeutics Journal.